Vivozon Overview
- Year Founded
-
2008
- Status
-
Private
- Latest Deal Type
-
2ndary - Private
- Financing Rounds
-
5
- Investments
-
4
Vivozon General Information
Description
Provider of drug development and drug discovery services intended to treat pain using its unique ex vivo screening technology. The company specializes in the discovery, development and commercialization of small molecule drugs for the treatment of patients with unmet CNS medical needs and focuses on the development of safe non-opioid, next-generation pain killers for patients suffering from operations, neuropathic pain, and cancer pain, enabling them to get relief from pains.
Contact Information
Website
www.vivozon.comCorporate Office
- D-9F/10F, 357, Guseong-ro
- Giheung-gu
- Yongin-si, Gyeonggi-do 16914
- South Korea
Corporate Office
- D-9F/10F, 357, Guseong-ro
- Giheung-gu
- Yongin-si, Gyeonggi-do 16914
- South Korea
Vivozon Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Vivozon Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Vivozon Patents
Vivozon Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026089567-A1 | Heterocyclic compound and use thereof | Pending | 25-Oct-2024 | ||
| WO-2026034972-A1 | Dual regulator for mglur5 and hdac6 and use thereof | Pending | 06-Aug-2024 | ||
| AU-2024240637-A1 | Double regulator for mglur5 and hdac6 and use thereof | Pending | 21-Mar-2023 | ||
| EP-4685143-A1 | Double regulator for mglur5 and hdac6 and use thereof | Pending | 21-Mar-2023 | ||
| WO-2024196136-A1 | Double regulator for mglur5 and hdac6 and use thereof | Inactive | 21-Mar-2023 | A61K31/4439 |
Vivozon Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Vivozon Investments & Acquisitions (4)
Vivozon’s most recent deal was a Merger/Acquisition with Inist. The deal was made on 28-Sep-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Inist | 28-Sep-2020 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| Clairvoyant Ventures | 01-Jan-2020 | Merger/Acquisition | Other Capital Markets/Institutions | ||
| Emmaus Life Sciences | 29-Oct-2019 | PIPE | Drug Discovery | ||
| Vivozon Pharmaceutical | 01-Jan-2019 | Merger/Acquisition | Fiberoptic Equipment |
Vivozon Exits (1)
Vivozon’s most recent exit was on 01-Jan-2020 from Clairvoyant Ventures. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Clairvoyant Ventures | 01-Jan-2020 | Completed |
|
Vivozon Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Vivozon Pharmaceutical | Seoul, South Korea | 2002 | |
| Inist | Yongin-si, South Korea | 2000 |
Vivozon FAQs
-
When was Vivozon founded?
Vivozon was founded in 2008.
-
Where is Vivozon headquartered?
Vivozon is headquartered in Yongin-si, South Korea.
-
What industry is Vivozon in?
Vivozon’s primary industry is Drug Discovery.
-
Is Vivozon a private or public company?
Vivozon is a Private company.
-
What is the current valuation of Vivozon?
The current valuation of Vivozon is .
-
What is Vivozon’s current revenue?
The current revenue for Vivozon is .
-
How much funding has Vivozon raised over time?
Vivozon has raised $94.7M.
-
Who are Vivozon’s investors?
Abion (Drug Discovery), Telcon RF Pharmaceutical, and Polaris AI Pharma have invested in Vivozon.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
